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Abstract:
Cardiovascular morbidity and mortality is  a major burden in patients type 2
diabetic mellitus (T2DM). In a landmark study, semaglutide (an injectable GLP-1
receptor  (GLP-1R)  agonist)  has  been  shown  to  significantly  reduce
cardiovascular (CV) events, however the mechanism of benefit is still unknown.
FDA regulated that all the diabetic medications have a cardiovascular (CV) trial
to assess the safety. Semaglutide has been shown to reduce CV events.  The
objective  of  this  randomized,  double‐blind,  placebo‐controlled  study  is  to
evaluate  the  effect  of  semaglutide  on  coronary  atherosclerotic  plaque
progression.  The primary endpoint of the study is to assess the quantitative
change in non-calcified plaque volume measured by multidetector computed
tomography  angiography  over  1  year.  Secondary  endpoints  include
quantitative changes in different coronary plaque types and morphology in type
2 diabetes mellitus (T2DM)ics. Furthermore, we will evaluate the relationship
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between plaque changes and atherosclerotic burden and plaque vulnerability
over the course of 1 year in persons with T2DM. 
Introduction:
Cardiovascular disease (CVD) is the principal cause of morbidity and mortality
in type 2 diabetes. According to the American College of Cardiology, adults with
diabetes are two to four times more likely to have heart disease or a stroke
than adults without diabetes (1). Treatment of this disease is challenging and
expensive,  involving  multiple  classes  of  antidiabetic  medications.  The  most
recent Centers of Disease Control and Prevention (CDC) data report states that
there are 30.3 million Americans with type 2 diabetes (T2DM), with 7.2 million
underdiagnosed (2). This disease costs more than $327 billion per year with
$237 billion in medical costs and $90 billion in lost productivity. (3). 
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ADOPT (A Diabetes Outcome Progression Trial) trial evaluated the A1c changes
over  a  5yrs  period  using  monotherapy  with  Metformin,  Glyburide  or
Rosiglitazone. (4) The increased risk of CV events with Rosiglitazone after the
ADOPT  Trial  made  led  to  changes  in  policy  with  the  Food  and  Drug
Administration  (FDA) to  regulate  that  all  diabetic  medications  have  a
cardiovascular trial to assess their safety. (5)
There are multiple classes of medications available to treat type 2 diabetes
with the goal of achieving an optimal  hemoglobin  A1C. However, very little is
known  concerning  the  relative  effectiveness  of  the  different  classes  of
antidiabetic  medications  to  promote  or  retard  the  progression  of
atherosclerosis in type 2 diabetes. This information is critical if physicians are
to reduce the primary cause of death in diabetic patients. Recent trials have
shown that  liraglutide  (glucagon like  peptide 1 analogue)  and empagliflozin
(selective inhibitor of sodium- glucose cotransporter 2) significantly reducedtion
of CV deaths from cardiovascular causes in patients with T2DM type 2 diabetes
mellitus who were at risk of cardiovascular events. (8,6) 
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Figure 1: Effects of GLP-1 on specific tissues.
Injectable  GLP-1  receptor  (GLP-1R)  agonists  mimic  endogenous  GLP-1  by
stimulating pancreatic insulin secretion with a low risk of hypoglycemia and
cause  significant  weight  loss  by  reducing  appetite  (figure  1).  (7,10)
Semaglutide,  a  newer GLP1 analogue, which  has  an extended half-life  of  1
week, hasve proven to reduces the cardiovascular mortality in diabetics T2DM
by  SUSTAIN-6  (semaglutide  and  cardiovascular  outcomes  in  patients  with
T2DM) trial. (6) Limited preliminary data suggest a marked difference in the
rate  of  coronary  atherosclerosis  progression  with  different  classes  of
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antidiabetic medications (9), but no randomized comparison clinical trials have
been  reported  with  the  most  commonly  prescribed  newest  classes  of
antidiabetic medications. This information is critical for both the type 2 diabetic
patients  and their  physicians  if  the  treatment  is  to  be optimized  to  reduce
cardiovascular  morbidity  and  mortality.  Our  study  will  provide  this  needed
mechanistic information to better understand the CV benefits, which will have a
major impact on the diabetes care of millions of Americans.
The objective of the study is to evaluate the effects of Semaglutide on reducing
the  progression  of  atherosclerotic  plaque,  measured  by  multidetector
computed tomography angiography (MDCTA)  over 1 year. With its  volumetric
quantitative  nature, MDCTA well suited to evaluate the presence, extent, and
severity  of  coronary  atherosclerotic  plaque burden and progression.  We will
evaluate this effect in the context of statin use, glycemic control, microvascular
disease and cardiovascular risk factors. 
Methods:
Study Design: 
This study is a single centered, randomized, double‐blinded, placebo‐controlled
trial being conducted at Los Angeles Biomedical Research Institute, California in
the  United  States  (NCT……).  Eligible  patients  will  be  randomly  assigned  to
semaglutide 2mg/1.5 ml (1.34 mg/ml) prefilled pen for SC injection or placebo
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1.5  ml,  pen-injector  for  SC injection  in  a  1:1  fashion  as  an add-on to  their
standard of care. Patients will be followed for 12 months, with a phone call 30
days after medication discontinuation. 
After randomization,  semaglutide or placebo will  be introduced at a dose of
0.25 mg/weekly. A fixed dose-escalation procedure will be used, with a starting
dose of 0.25 mg for 1 month that is escalated to 0.5 mg as per protocol in
SUSTAIN-6.  After an additional 4 weeks, the dosage will be increased to 1 mg
once weekly.  Dose increase period can be extended based on the subject’s
tolerance to the trial product. If the maximum dose of 1 mg once weekly is not
tolerated or otherwise associated with unacceptable adverse events, reduction
in the dose to 0.5 mg/week is allowed at the investigator’s discretion.   Subjects
unable to tolerate 0.5 mg/week will be dropped from the study.  Injection can
be  done  at  any  time  of  the  day  and  irrespective  of  meals.  It  will  be
recommended that  the time of  injection  is  consistent  from one injection  to
another. 
If a subject misses a dose of investigational product during the trial, they will
be instructed to take it as soon as possible within 5 days after the missed dose.
If more than 5 days have passed, they will  be instructed to skip the missed
dose and administer the next dose on the regularly scheduled day. In each
case,  patients  can then resume their  regular  once weekly  dosing schedule.
Subjects should be instructed not to “make-up” for the missed dose by taking a
double  dose  at  the  same  time.  The  day  of  weekly  administration  can  be
8
changed if necessary, as long as the time between two doses is at least 2 days
(> 48 hours).
Baseline examination will  include the results of their demographics, physical
examination and an evaluation of blood pressure, height, weight and laboratory
blood testing. All participants will be educated on an ADA diet at entry to the
study.   Baseline  information  regarding  risk  factors  for  atherosclerotic
cardiovascular  disease  (cigarette  smoking  status,  systemic  hypertension,
family  history  of  premature  atherosclerosis,  menopausal  and  hormone
replacement status in women, sedentary lifestyle, current medications, chest
pain questionnaire and measures of obesity) will be determined.  CCTA, using
state‐of‐the‐art MDCTA technology, will  be used to evaluate coronary plaque
volume/composition. The evaluations of plaque using CCTA will be repeated at
month 12. Adverse events will be monitored throughout the study. The study
schematic is shown in Figure 2. 
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   Figure 2: Study Schematic
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Study population:
Inclusion and exclusion criteria were included in Table 1. The eligible patients
will be age  > 40yrs with HbA1c  > 7 or more and coronary atherosclerosis
(narrowing  > 20% in 1 coronary artery) by Cardiac Computed Tomography
Angiography (CCTA).
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Table 1: Key Inclusion and Exclusion Criteria
        Inclusion Criteria
 Men or women with type 2 diabetes with a glycated hemoglobin level of 7.0% or
more drug naïve or treated with oral agents and/or basal insulin.  For patients on
basal  insulin  at  entry,  the  PI  will  consider  dose  reduction  of  basal  insulin
according to A1c and risk for hypoglycemia.  Patients on SGLT-2 inhibitors may
be  screened  but  the  agents  must  be  discontinued  at  least  30  days  prior  to
randomization.
 Age >   40 years of age 
 Patients  with  a  diagnosis  of  T2DM  in  accordance  with  American  Diabetes
Association  (ADA) guidelines and with at least one cardiovascular  risk factor
(hypertension, high cholesterol, family history of premature heart disease or
past/current smoking) or prior ASCVD (prior stroke, TIA, claudication, coronary
artery disease)
 Written informed consent
Exclusion Criteria
 History of type 1 diabetes mellitus 
 History of ketoacidosis.
 Current use of GLP-1–receptor agonists or use of a GLP-1 receptor agonist within 3
months of screening
 Current Use of SGLT-2 inhibitors within 30 days of screening
 Patients on prandial insulin or using an insulin pump or pramlintide.
 History of  one  or  more  severe  hypoglycemic  episodes  within  6  months  of
Screening (V1) or a severe hypoglycemic episode occurring during the interval
between the Screening visit (V1) and randomization.
 Patients  experiencing  a  cardiovascular  event  (e.g., myocardial  infarction  or
stroke)  or  undergoing  coronary angioplasty or  peripheral  intervention
procedure between the Screening visit (V1) and randomization.
 Recent ASCVD Event (stroke, heart attack, ACS or revascularization) within 3
months (90 days) of the screening visit (VI).
 Undergoing any cardiovascular surgery (e.g., valvular surgery) within 3 months (90
days) of the Screening visit (V1).
 Any planned coronary revascularization  or  peripheral  intervention  procedure  or
other cardiovascular surgery.
 History of New York Heart Association (NYHA) Class III or IV heart failure at the
Screening visit (V1).
 Renal insufficiency (calculated creatinine clearance of <50 ml per minute, MDRD
equation).
 AST or ALT >2 X the upper limit of normal (ULN) at the Screening visit (V1), or a
total bilirubin >1.5 X the ULN unless the subject has a history of Gilbert’s.
 Weight in excess of 325 pounds
 Resting hypotension (systolic blood pressure of <90mmHg) or resting hypertension
(systolic  blood  pressure  of  >170mmHg  or  diastolic  blood  pressure  of  >110
mmHg) 
 History of malignancy ≤5 years prior to signing informed consent
 Pregnancy
 Currently enrolled in another placebo-controlled trial.
 Family  or  history  of  multiple  endocrine  neoplasia  type  2  (MEN2)  or  familial
medullary thyroid carcinoma (FMTC)
 History of non-familial medullary thyroid carcinoma.
 Known or suspected hypersensitivity to trial products.
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Study endpoints
         Primary Endpoint 
 The primary objective of   study is to assess the quantitative change in
non-calcified plaque volume over 1 year.  
 Secondary Endpoints 
 Assess  incident  plaque  rates  and  quantitative  changes  in  different
plaque  types  including  calcified and different  forms  of  non-calcified
atherosclerosis  including  fibrous,  fibrous-fatty,  and  low  attenuation
plaque in patients with type 2 diabetes who are on a standard of care
regimen receiving once-weekly semaglutide or placebo with CCTA, 12
months after an initial evaluation.
 Evaluation of  plaque progression rates  and incident  plaque rates  in
subjects treated with semaglutide and placebo. In that context, we will
determine whether subjects treated with semaglutide display slower
rates  of  progression  compared  to  placebo  treated  subjects,  after
control  for  all  CV  risk  factors,  diabetes  control,  concomitant
medications and demographics
Statistical Design and Analysis 
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The primary outcome will be the intention to treat per-subject rate of change
in the coronary atherosclerotic burden. CCTA outcomes obtained at the end-
of-treatment  will  be  compared  between  treatment  groups  as  described
above:  1)  primary  CCTA measures  –  non-calcified  plaque  volume change
over  time;  and,  2)  secondary CCTA measures  –  individual  components  of
plaque including low attenuation, fibro-fatty, fibrous and calcified plaques.
CAC measures, as a secondary outcome, will include presence of any CAC
(dichotomous  variable)  and  CAC  score,  as  well  as  changes  in  LV  mass
between  assignment  groups.  General  linear  models  (GLM)  will  be  used,
specifying  these  CCTA  and  CAC  measures  as  dependent  variables.  The
baseline measures of the same outcomes (CAC and CCTA outcomes) will be
included as covariates. To account for the fact that the end-of-treatment visit
will differ across subjects, indicator variables for the study visit at which the
CAC and CCTA measures were obtained will also be included as covariates
The primary analysis will compare the semaglutide group to placebo group
(Objective  1).  Accounting  for  the  comparison,  conservative  sample  size
calculations can be obtained at the nominal two-sided alpha level of 0.05.  
For  sample size determination,  the following  assumptions  on the efficacy
variable of the changes in non-calcified plaque from baseline are considered:
 A standard deviation of 6 mm3 for the primary variable
 A treatment difference of at least 12 mm3 in non-calcified plaque in favor
of semaglutide vs. placebo 
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Allowing for  15% dropouts,  a total  sample size of  140 participants  (120
after dropout),  consisting of final of 60 subjects each in the semaglutide
and placebo group, provides 0.898% power at level 0.05.
In  the  field  of  atherosclerosis  progression  imaging  (with  intravascular
ultrasound,  computed  tomographic  angiography  or  coronary  artery
calcification),  the  primary  outcome  is  a  statistical  difference  between
groups, suggesting that the intervention slows atherosclerosis compared to
the control arm. Prior studies using CCTA have ranged in size from 40 to
140  participants,  each  showing  significant  differences  between
arms. Studies  have  included  statins  (40  and  100  persons),  anti-
inflammatories (54 persons), garlic therapy (55 persons) and testosterone
(140 persons) (6, 8-10). New studies with novel oral anti-coagulants have
each shown differences in randomized studies performed by the core lab at
LA  BIOMED,  with  total  sample  sizes  of  66  and  120  respectively,  each
demonstrating significant  differences between active agent  and placebo.
Each  study  demonstrated  a  statistically  significant  difference  between
groups,  and  the  effect  size  varied  from  24-40  mm3.  Thus,  to  be
conservative, we are powering this study with an effect size of 12 mm3, to
ensure that if differences in rates of progression are occurring, we will be
well powered to visualize those changes. 
Compliance
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After  randomization,  participants  will  return  at  1  month  for  titration  of
medication,  then  quarterly  (months  3,  6,  9  and  12  months  to  assess
compliance with medication, and receive an additional supply of medicine.
Between 3-month visits, we will  have an inter-trial phone visit   to ensure
improved  study  medication  adherence  and  compliance  during  dose
escalation and maintenance.
Ethical considerations and study organization
The current study is being conducted in compliance with Institutional Review
Boards  (IRB)/Institutional  Ethics  Committees  (IEC),  the  principles  of  the
Declaration of Helsinki, the International Conference on Harmonisation (ICH),
Good Clinical Practice guidelines (GCP),  Code of Federal Regulations (CFR)
and  relevant  local  laws  and  regulations.  All  patients  will  provide  written
informed consent. The Data Safety Monitoring Board will  meet at 6‐month
intervals to monitor study progress, safety, and efficacy.  All personnel will
follow our institution standard operations Procedure “SOP: Informed Consent
Process for Research (HRP-090)”
Study status
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As of June 2019, tThe study was approximately 30% enrolled with an 
estimated study enrollment completion by first quarter of 2020, and 
end of study by first quarter 2021.
Discussion
Our  study  protocol  is  a  natural  extension  of  the  results  of  LEADER
(liraglutide  effect  and  action  in  diabetes:  Evaluation  of  cardiovascular
outcome results)  and  SUSTAIN  6.  This  study  provides  an opportunity  to
evaluate  the  anti-atherogenic  potential  of  semaglutide,  providing  a
mechanism of CV benefit.  We will randomize patients with type 2 diabetes
who are on a standard of care regimen (similar to LEADER and SUSTAIN 6,
table 2) to receive once weekly semaglutide or placebo. This is crucial to
our  understanding  of  DM treatment  and  CVD,  since  plaque  progression
portends worse outcomes in these populations. (1,9) While CVD represents
a critical source of morbidity and mortality, there exist few data to support
the preference of any specific glucose-lowering regimen to prevent these
complications.  Furthermore,  proof  of  slowing  atherosclerosis  could  have
specific applications for certain regimens in those persons with co-existent
ASCVD and DM.  The focus on individual demographic, clinical, and plaque
factors  that  may  influence  a  differential  coronary  plaque  response  to
medications will add to our understanding of therapy for T2DM. The major
aim of this study is to assess the impact of semaglutide on coronary artery
atherosclerosis progression. 
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     Table 2.  Standard of Care Regimen
In the LEADER trial, 9340 patients with type 2 diabetes at high CV risk were
randomized  to  receive  the  longer-acting  drug  liraglutide  1.8  mg  (or
maximum tolerated dose) or matching placebo once daily and followed for
a median of 3.8 years.(11) There was a 13% statistically significant (P <
0.001 for noninferiority, P < 0.01 for superiority) reduction in the primary
end point, including a 22% reduction cardiovascular mortality (P = 0.007)
and 15% reduction in total mortality (P = 0.02). (11) Other evaluations of
longer-acting  GLP-1R    agonists  include  semaglutide,  once-weekly
exenatide, and dulaglutide. (12) The long-term cardiovascular outcomes of
semaglutide were investigated in the SUSTAIN-6 trial, which recruited 3297
patients  with type 2 diabetes,  of  whom 83% had established CVD.  Two
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dosage levels of 0.5 and 1.0 mg of semaglutide and placebo once weekly
were compared in addition to conventional therapy. (13,14) During a 2.1-
year median follow-up, the primary composite outcome of cardiovascular
death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.6% of
patients in the semaglutide group and in 8.9% in the placebo group (HR =
0.74;  95%  CI,  0.58–0.95;  P  <  0.001  for  noninferiority,  P  =  0.02  for
superiority). (15)
The  US  Food  and  Drug  Administration  (FDA)  has  approved  Victoza®
(liraglutide) injection 1.2 mg or 1.8 mg to reduce the risk of major adverse
cardiovascular  events  (cardiovascular  death,  non-fatal  myocardial
infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and
established  CVD.  (16,17)  There  is  also  robust  myocardial  infarction  and
stroke reduction seen in SUSTAIN-6 (26 and 39% respectively) that further
enhances  the  likelihood  that  this  effect  is  likely  related  to  effects  on
atherosclerosis.  Recently,  the FDA approved  Ozempic® (semaglutide) as
well  to  improve  the  cardiovascular  outcomes  in  T2DM.  (6,18)  The  clear
reduction in end points in the LEADER and SUSTAIN trials, may represent an
anti-atherosclerotic  effect  of  the  GLP-1R  agonists,  liraglutide  and
semaglutide. (19,20)  To further elucidate the  mechanism of hypothesized
anti-atherosclerotic  effect of semaglutide, our current study will  evaluate
the association between pre and post treatment MDCTA (changes in plaque
components, stenosis and coronary calcium) and distinct biomarkers. 
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MDCTA  is  a  new  technique  and  have  high  reproducibility  with  <1%
variability for non-calcified and calcified plaque volume measure, and < 15
%  variability  for  total  plaque  volume.  (21)  MDCTA  is  a  noninvasive
procedure  which provides  an information of  plaque composition,  volume
and severity of coronary vessel stenosis. (22) This technique is now widely
used  now a days  in clinical investigations for the efficacy of therapies on
coronary  plaque  progression  including  garlic,  statinstestosterone,
inflammatory agents, eicosapentaenoic acid (EPA) and various antidiabetic
agentsanti-coagulants. (21-28)
The changes over time seen in the MDCTA scans (plaque volume, severity,
and calcification) will assess the anti-atherosclerotic affects of semaglutide,
while  the  biomarkers  and  assessment  of  new  and  existing  vulnerable
plaque, will assess the potential biological effects on the vasculature (ie –
inflammation, plaque stabilization) in our current study.  Further, changes
over time seen on the CT (ie – soft plaque becoming fibrous or calcified) will
inform clinicians relative to the long term stabilization of  atherosclerosis
that may be seen with Semaglutide during the study.  
Conclusion:
Our current study will be the first one to evaluate the effects of semaglutide
on  atherosclerotic  plaque  progression  measured  by  MDCTA  in  T2DM
individuals  and  it  will  also  assess  whether  these  effects  correlate  with
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HbA1c  changes  and  inflammatory  markers.  This  study will  provide  anti-
atherosclerotic  mechanism of  long acting GLP-1 there by preventing the
coronary events in T2DM.
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